Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...

President Donald Trump announced major GLP-1 drug price cuts with Eli Lilly and Novo Nordisk, reducing costs for Ozempic and Wegovy.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, ...

Shares in Novo Nordisk fell as much as 3 per cent on Friday after the Danish drugmaker and U.S. rival Eli Lilly agreed with ...

Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo Nordisk, special vouchers that will speed up the review of their medicines, ...

Obesity products gain momentum in India and globally as multinationals leverage smart pricing and collaborations amidst ...